Clinical Trial

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-01-27; most recent amendment 2026-02-09.
Status change: Recruiting → Active, Not Recruiting 2026-02-09
Status change: Not Yet Recruiting → Recruiting 2025-07-08
Trial Details
NCT Number NCT06803342
Lead Sponsor Albert B. Sabin Vaccine Institute
Collaborators: Biomedical Advanced Research and Development Authority
Conditions Ebola Sudan Virus Disease
Enrollment 200 participants
Start Date 2025-06-26
Primary Completion 2027-02 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-10